Clinical Trials - No Longer Enrolling
| Clinical Trial | Study Result Published |
|---|---|
| Neuroimaging & Biomarkers Study - ADNI: Normal Aging, Mild Cognitive Impairment & Early Alzheimer's Disease | Over 100 Study publications |
| Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Kurlan R, Cummings J, Raman R, Thal L for the Alzheimer's Disease Cooperative Study Group Neurology. 2007 April 24: 68; 1356-1363 |
| Vitamins to Slow Alzheimer's Disease (Homocysteine Study) (VITAL) | High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial |
| Mild Cognitive Impairment Study Aricept, Vitamin E or Placebo | Vitamin E and donepezil for the treatment of mild cognitive impairment. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group, N Engl J Med. 2005 Jun 9; 352(23):2379-88. Epub 2005 Apr 13 |
| DHA, an Omega 3 Fatty Acide, in Slowing the Progression of Alzheimer's Disease | Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial |
| RAGE (Receptor for Advanced Glycation Endproducts) Inhibitor Study | PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease |
| Racial Disparities in ADL's |
